Hydrogen therapy may be an effective and specific novel treatment for Acute Graft-versus-host disease (GVHD)

Liren Qian a, *, Jianliang Shen a, *

a Department of Haematology, Navy General Hospital, Beijing, China

Received: March 4, 2013; Accepted: April 3, 2013

Abstract

Allogeneic haematopoietic stem cell transplantation (HSCT) has been widely used for the treatment of haematological malignant and non-malignant haematologic diseases. However, acute graft-versus-host disease (aGVHD) is a kind of severe complication of HSCT limiting its application. Cytokines such as tumour necrosis factor-α (TNF-α), IL-6 play an extremely important role in the formation and development of aGVHD. Besides, the oxidation phenomena and/or the formation of free radicals have been suggested to be causally related to various haematological disorders including aGVHD. Reactive oxygen species (ROS), such as hydroxyl radicals, play an important role in the formation and development of aGVHD. Hydrogen has been reported to have the ability to inhibit levels of cytokines such as TNF, IL-6 in vivo. Our recent studies provided evidence that hydrogen inhalation can selectively reduce cytotoxic oxygen radicals and exert antioxidant effects. Therefore, we suggested that hydrogen may have therapeutic effects on aGVHD. This hypothesis entails many experimentally testable predictions. We propose the experimental study by detecting complete blood counts (CBC) and Clinic signs of aGVHD mice. We also propose to detect the levels of TNF-α, IL-2, IL-1β, IL-6 which play important roles in the pathogenesis of aGVHD. To discover potential mechanisms of the therapeutic effects of hydrogen on the aGVHD model, we will examine gene-expression profiles. This study will open a new therapeutic avenue combining the field of therapeutic medical gases and aGVHD. This theory is original and probably of importance, because therapeutic medical gases have never been used for aGVHD previously.

Keywords: Hydrogen • graft-versus-host disease • antioxidant • cytokine

Background

Hydrogen is the most abundant chemical element. Hydrogen gas has been extensively used in chemical field such as fuel processing, fertilizer production (3H2 + N2 → 2NH3) and so on. It is a colourless, odourless, non-metallic, tasteless, highly flammable diatomic gas which was considered as a physiological inert gas.

Early in 1975, Dole et al. [1] found that inhalation of a mixture (2.5% O2 and 97.5% H2) at a total of 0.8 MPa for 2 weeks caused a marked regression of the skin squamous cell carcinoma in a mouse model, and they tried to elucidate the phenomenon with the possibility of H2 as a free radical decay catalyst. In 1988, a paper by Buxton et al. [2] demonstrated that H2 could reduce hydroxyl radicals (·OH) produced by radiolysis or photolysis of H2O in cell-free systems. In 2001, it was demonstrated that schistosomiasis-associated chronic liver inflammation was significantly attenuated by one normal atmosphere supplemented with 0.7 MPa H2 in mice [3]. However, these investigations did not draw attention from researchers.

In 2007, Ohsawa et al. [4] discovered that hydrogen gas has antioxidant and antiapoptotic properties that protect the brain against ischaemia–reperfusion injury and stroke by selectively neutralizing hydroxyl and peroxynitrite radicals. Since then, hydrogen gas has come to the forefront of therapeutic medical gas research. Recent basic and clinical research has revealed that hydrogen is an important physiological regulatory factor with antioxidant, anti-inflammatory and antiapoptotic protective effects on cells and organs [5–10], proving that hydrogen could down-regulate cytokines, including CCL2, IL-1β, IL-6, IL-12, TNF-α, etc. We also have proposed and proved that hydrogen has radioprotective effects in cultured cells and mice [11–17]. It also has been demonstrated that H2 is effective in the prevention of cerebral, myocardial, hepatic ischaemia–reperfusion injuries and other injuries [18, 19].

Since 2009, hydrogen was applied on the field of organ transplantation including intestinal transplantation, lung transplantation, renal transplantation and heart transplantation. It was demonstrated that hydrogen could protect allograft function in those models [19–23]. However, the potential effect of hydrogen gas on another
transplantation type is largely ignored. That type is the allogeneic hematopoietic stem cell transplantation.

**Presentation of the hypothesis**

Allogeneic HSCT is a potentially curative therapy for many malignant hematologic disorders, while it is restricted by its severe complications. One major complication associated with HSCT is aGVHD, which is a major cause of death following allo-HSCT. Three complex stages are involved in the pathophysiology of aGVHD [24]. Stage I involves tissue damage and cellular activation induced by preconditioning. Stage II involves activation of donor lymphocytes (T cells). In Stage III, cellular and inflammatory factors are released, including TNF-α, interleukin (IL)-1 and IL-6 et al. These cytotoxic molecules directly attack various host tissues and underlie the clinical manifestations of aGVHD [25, 26]. The activated cells also produce a large number of harmful free radicals resulting in severe cell damage, which also play an important role in the development of aGVHD [27].

Nowadays, the standard initial therapy for aGVHD includes the use of high-dose steroids, which results in about 40% complete response (CR) rate [28]. This CR rate is unsatisfactory, and in patients who have less than a CR, there is high mortality, both from the aGVHD itself and from the steroid-related infectious complications. Treatment of steroid-resistant aGVHD is very difficult, with many institutions using monoclonal antibody treating steroid-resistant aGVHD patients, including anti-TNF-α monoclonal antibody (mAb), anti-CD52 mAb, anti-CD47 mAb (ABX.CBL), anti-CD3 mAb, et al. But their therapeutic effects are not ideal, while with high infection rate. Overall, those treatments of aGVHD did not achieve significant breakthroughs. Various researchers have engaged in identifying novel, non-toxic, effective and convenient drugs to cure or alleviate aGVHD.

Our hypothesis is that hydrogen gas may have therapeutic effects on aGVHD. Our hypothesis is based on the theory that hydrogen could down-regulate cytokines, CCL2, IL-1β, IL-6, IL-12, TNF-α, et al. and selectively reduce hydroxyl and peroxynitrite radicals (Fig. 1). In addition, H₂ has other advantages; it has demonstrated that H₂ has...
non-toxicity at any pressure [29]. It can penetrate biomembranes and diffuse into the cytosol, mitochondria and nucleus to protect nuclear DNA and mitochondria [30]. As those cytokines including IL-6, IL-1, TNF-α, et al. and free radicals have been suggested to play great important roles in the formation and development of aGVHD as discussed above, we suggested that hydrogen gas may be potentially effective for aGVHD by down-regulating cytokines and selectively reducing hydroxyl and peroxynitrite radicals.

Testing the hypothesis

For testing the hypothesis, hydrogen gas could be administered by two ways: First, it may be administered to patients via inhalation as room air at safe concentrations (<4.6% in air by volume). Second, we can dissolve hydrogen gas into water delivering it as drinking water. This may be more practical in daily life and more suitable for daily consumption for therapeutic use. Hydrogen-rich drinking water can be generated by several methods including dissolving electrolysed hydrogen into pure water, dissolving hydrogen into water under high pressure and utilizing electrochemical reaction of magnesium with water. We propose the experimental study by detecting CBC, Clinic signs of aGVHD (weight loss, posture, activity, fur change, skin integrity) as described previously [31, 32]. We also propose to detect the levels of TNF-α, IL-2, IL-1β, IL-6 as described previously [33, 34], which have been demonstrated to play important roles in the pathogenesis of aGVHD. And plasma malondialdehyde (MDA), 8-hydroxyguanosine (8-OHdG) and endogenous antioxidants such as SOD, GSH will also be detected in vivo. To discover potential mechanisms of the therapeutic effects of hydrogen on the aGVHD model, we will examine gene-expression profiles, such as expression of Bcl-2, Bax, Caspase-3, Caspase-8 [35, 36]. On the basis of these experimental designs, we preliminarily demonstrated the therapeutic effects of hydrogen on aGVHD in a mice model [37]. We demonstrated that hydrogen treatment could protect mice from lethal GVHD and improve clinic syndrome of aGVHD mice and also could promote the recovery of white blood cells of aGVHD mice. We also examined serum cytokine levels. Cytokines, such as TNF-α, IL-2 were also reduced by hydrogen, which play critical roles in the development of aGVHD (Fig. 2).

Implications of the hypothesis

This study will open a new therapeutic avenue combining the field of therapeutic medical gases and aGVHD. This theory is original and probably of importance, because therapeutic medical gases has never been used for aGVHD previously. We believe that in vitro and in vivo work for hydrogen gas on aGVHD would come in great numbers as soon as possible. In view of the high lethality rate of aGVHD, hydrogen gas may give us more hope for greater survival with few side effects.

Acknowledgements

This work was supported by a grant from the National Natural Science Foundation of China (grant no. 81072241).

Conflicts of interest

The authors confirm that there are no conflicts of interest.
combine radiotherapy with aerosol inhalation of hydrogen-rich solution. *Med Sci Monit.* 2011; 17: HY1–4.

15. **Qian L, Li B, Cai J, et al.** The hypothesis of an effective safe and novel radioprotective agent: hydrogen-rich solution. *West Indian Med J.* 2010; 59: 122–4.

16. **Qian L, Cao F, Cui J, et al.** The potential cardioprotective effects of hydrogen in irradiated mice. *J Radiat Res.* 2010; 51: 741–7.

17. **Qian L, Cao F, Cui J, et al.** Radioprotective effect of hydrogen in cultured cells and mice. *Free Radic Res.* 2010; 44: 275–82.

18. **Hayashida K, Sano M, Ohawa I, et al.** Inhalation of hydrogen gas reduces infarct size in the rat model of myocardial ischemia-reperfusion injury. *Biochem Biophys Res Commun.* 2008; 373: 30–5.

19. **Buchholz BM, Kaczorowski DJ, Sugimoto R, et al.** Hydrogen inhalation ameliorates oxidative stress in transplantation induced intestinal graft injury. *Am J Transplant.* 2008; 8: 2015–24.

20. **Kawamura T, Huang CS, Tochigi N, et al.** Inhaled hydrogen gas therapy for prevention of lung transplant-induced ischemia/reperfusion injury in rats. *Transplantation.* 2010; 90: 1344–51.

21. **Cardinal JS, Zhan J, Wang Y, et al.** Oral hydrogen water prevents chronic allograft nephropathy in rats. *Kidney Int.* 2010; 77: 101–9.

22. **Nakao A, Kaczorowski DJ, Wang Y, et al.** Amelioration of rat cardiac cold ischemia/reperfusion injury with inhaled hydrogen or carbon monoxide, or both. *J Heart Lung Transplant.* 2010; 29: 544–53.

23. **Kawamura T, Huang CS, Peng X, et al.** The effect of donor treatment with hydrogen on lung allograft function in rats. *Surgery.* 2011; 150: 240–9.

24. **Vodanovic-Jankovic S, Hari P, Jacobs P, et al.** NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. *Blood.* 2006; 107: 827–34.

25. **Hill GR, Crawford JM, Cooke KR, et al.** Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. *Blood.* 1997; 90: 3204–13.

26. **Hill GR, Teshima T, Gerblitz A, et al.** Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. *J Clin Invest.* 1999; 104: 459–67.

27. **Ferrara JL, Deeg HJ.** Graft-versus-host disease. *N Engl J Med.* 1991; 324: 667–74.

28. **Abo-Zena RA, Horwitz ME.** Immunomodulation in stem-cell transplantation. *Curr Opin Pharmacol.* 2002; 2: 452–7.

29. **Fontanari P, Badier M, Guilhot C, et al.** Changes in maximal performance of inspiratory and skeletal muscles during and after the 7.1-MPa Hydra 10 record human dive. *Eur J Appl Physiol.* 2000; 81: 325–8.

30. **Liu C, Cui J, Sun Q, et al.** Hydrogen therapy may be an effective and specific novel treatment for acute radiation syndrome. *Med Hypotheses.* 2010; 74: 145–6.

31. **Cooke KR, Kobzik L, Martin TR, et al.** An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. *Blood.* 1996; 88: 3230–9.

32. **MacDonald KP, Rowe V, Filippich C, et al.** Donor pretreatment with progenipoietin-1 is superior to granulocyte colony-stimulating factor in preventing graft-versus-host disease after allogeneic stem cell transplantation. *Blood.* 2003; 101: 2033–42.

33. **Wang F, Yu G, Liu SY, et al.** Hydrogen-rich saline protects against renal ischemia/reperfusion injury in rats. *J Surg Res.* 2011; 167: e339–44.

34. **Sun Q, Cai J, Zhou J, et al.** Hydrogen-rich saline reduces delayed neurologic sequelae in experimental carbon monoxide toxicity. *Crit Care Med.* 2011; 39: 765–9.

35. **Bureau F, Vanderplasch W, Jaspar F, et al.** Constitutive nuclear factor-kappaB activity preserves homeostasis of quiescent mature lymphocytes and granulocytes by controlling the expression of distinct Bcl-2 family proteins. *Blood.* 2002; 99: 3683–91.

36. **Dai C, Krantz SB.** Interferon gamma induces upregulation and activation of caspases 1, 3, and 8 to produce apoptosis in human erythroid progenitor cells. *Blood.* 1999; 93: 3309–16.

37. **Qian L, Mei K, Shen J, et al.** Administration of hydrogen-rich saline protects mice from lethal acute graft-versus-host disease (aGVHD). *Transplantation.* 2013; 95: 658–62.

38. **Ferrara JLM.** Novel strategies for the treatment and diagnosis of graft-versus-host disease. *Best Pract Res Clin Haematol.* 2007; 20: 91–7.